Database : MEDLINE
Search on : Tonsillar and Neoplasms [Words]
References found : 3087 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 309 go to page                         

  1 / 3087 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29443738
[Au] Autor:Qin Y; Lu L; Lu Y; Yang K
[Ad] Address:Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan.
[Ti] Title:Hodgkin lymphoma involving the tonsil misdiagnosed as tonsillar carcinoma: A case report and review of the literature.
[So] Source:Medicine (Baltimore);97(7):e9761, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:RATIONALE: Primary Hodgkin lymphoma (HL) involving the tonsil is extremely rare. Only about 20 such cases with verification of biopsy and immunohistochemistry have been reported. Because of its rarity and unremarkable clinical presentation, a timely correct diagnosis is very challenging. PATIENT CONCERNS: A 43-year-old man complained left tonsillar enlargement and painless masses in left neck, with night sweat. The clinical examination found a marked tonsillar asymmetry, with an enlarged left tonsil and ipsilateral cervical lymphadenopathy and a normal right tonsil. DIAGNOSIS: The patient was initially regarded as tonsillar lymphoepithelial carcinoma. INTERVENTIONS: The patient received a resection of left tonsil and left cervical masses and then was definitively diagnosed as HL (IIEB). He was managed by 6 cycles of chemotherapy (adriamycin, bleomycin, vinblastine, and dacarbazine) and radiotherapy to the Waldeyer ring. OUTCOMES: The patient has been disease free for more than 3 years after diagnosis. LESSONS: As the reason of an extreme rare occurrence of HL involving the tonsil, doctors can easily misdiagnose the disease as tonsillar lymphoepithelial carcinoma. This case serves as a reminder important role of biopsy.
[Mh] MeSH terms primary: Carcinoma/diagnosis
Diagnostic Errors
Hodgkin Disease/diagnosis
Tonsillar Neoplasms/diagnosis
[Mh] MeSH terms secundary: Adult
Hodgkin Disease/drug therapy
Humans
Male
Palatine Tonsil/pathology
Palatine Tonsil/surgery
Tonsillar Neoplasms/drug therapy
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Em] Entry month:1802
[Cu] Class update date: 180222
[Lr] Last revision date:180222
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180215
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009761

  2 / 3087 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29338018
[Au] Autor:Marcussen M; Sønderkær M; Bødker JS; Andersen M; Nielsen S; Vesteghem C; Christiansen I; Bergmann OJ; Bøgsted M; Dybkær K; Vyberg M; Johnsen HE
[Ad] Address:Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
[Ti] Title:Oral mucosa tissue gene expression profiling before, during, and after radiation therapy for tonsil squamous cell carcinoma.
[So] Source:PLoS One;13(1):e0190709, 2018.
[Is] ISSN:1932-6203
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Radiation-therapy (RT) induces mucositis, a clinically challenging condition with limited prophylactic interventions and no predictive tests. In this pilot study, we applied global gene-expression analysis on serial human oral mucosa tissue and blood cells from patients with tonsil squamous cell cancer (TSCC) to identify genes involved in mucositis pathogenesis. METHODS AND FINDINGS: Eight patients with TSCC each provided consecutive buccal biopsies and blood cells before, after 7 days of RT treatment, and 20 days following RT. We monitored clinical mucositis and performed gene-expression analysis on tissue samples. We obtained control tissue from nine healthy individuals. After RT, expression was upregulated in apoptosis inducer and inhibitor genes, EDA2R and MDM2, and in POLH, a DNA-repair polymerase. Expression was downregulated in six members of the histone cluster family, e.g., HIST1H3B. Gene expression related to proliferation and differentiation was altered, including MKI67 (downregulated), which encodes the Ki-67-proliferation marker, and KRT16 (upregulated), which encodes keratin16. These alterations were not associated with the clinical mucositis grade. However, the expression of LY6G6C, which encodes a surface immunoregulatory protein, was upregulated before treatment in three cases of clinical none/mild mucositis, but not in four cases of ulcerative mucositis. CONCLUSION: RT caused molecular changes related to apoptosis, DNA-damage, DNA-repair, and proliferation without a correlation to the severity of clinical mucositis. LY6G6C may be a potential protective biomarker for ulcerative mucositis. Based on these results, our study model of consecutive human biopsies will be useful in designing a prospective clinical validation trial to characterize molecular mucositis and identify predictive biomarkers.
[Mh] MeSH terms primary: Carcinoma, Squamous Cell/genetics
Gene Expression Profiling
Mouth Mucosa/metabolism
Tonsillar Neoplasms/genetics
[Mh] MeSH terms secundary: Aged
Carcinoma, Squamous Cell/radiotherapy
DNA Damage
DNA Repair
Female
Humans
Middle Aged
Tonsillar Neoplasms/radiotherapy
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Entry month:1802
[Cu] Class update date: 180221
[Lr] Last revision date:180221
[Js] Journal subset:IM
[Da] Date of entry for processing:180117
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0190709

  3 / 3087 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29443638
[Au] Autor:Chen W; Shimane T; Kawano S; Alshaikh A; Kim SY; Chung SH; Kim RH; Shin KH; Walentin K; Park NH; Schmidt-Ott KM; Kang MK
[Ad] Address:1 The Shapiro Family Laboratory of Viral Oncology and Aging Research, UCLA School of Dentistry, Los Angeles, CA, USA.
[Ti] Title:Human Papillomavirus 16 E6 Induces FoxM1B in Oral Keratinocytes through GRHL2.
[So] Source:J Dent Res;:22034518756071, 2018 Feb 01.
[Is] ISSN:1544-0591
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:High-risk human papillomavirus (HPV) is a major risk factor for oral and pharyngeal cancers (OPCs), yet the detailed mechanisms by which HPV promotes OPCs are not understood. Forkhead box M1B (FoxM1B) is an oncogene essential for cell cycle progression and tumorigenesis, and it is aberrantly overexpressed in many tumors. We previously showed that FoxM1B was the putative target of an epithelial-specific transcription factor, Grainyhead-like 2 (GRHL2). In the current study, we demonstrate that HPV type 16 (HPV-16) E6 induces FoxM1B in human oral keratinocytes (HOKs) and tonsillar epithelial cells (TECs) in part through GRHL2. FoxM1B was barely detectable in cultured normal human oral keratinocytes (NHOKs) and progressively increased in immortalized HOKs harboring HPV-16 genome (HOK-16B) and tumorigenic HOK-16B/BaP-T cells. Retroviral expression of HPV-16 E6 and/or E7 in NHOKs, TECs, and hypopharyngeal carcinoma cells (FaDu) revealed induction of FoxM1B and GRHL2 by the E6 protein but not E7. Both GRHL2 and FoxM1B were strongly induced in the epidermis of HPV-16 E6 transgenic mice and HPV oral squamous cell carcinomas. Ectopic expression of FoxM1B led to acquisition of transformed phenotype in HOK-16B cells. Loss of FoxM1B by lentiviral short hairpin RNA vector or chemical inhibitor led to elimination of tumorigenic characteristics of HOK-16B/BaP-T cells. Luciferase reporter assay revealed that GRHL2 directly bound and regulated the FoxM1B gene promoter activity. Using epithelial-specific Grhl2 conditional knockout mice, we exposed wild-type (WT) and Grhl2 KO mice to 4-nitroquinolin 1-oxide (4-NQO), which led to induction of FoxM1B in the tongue tissues and rampant oral tumor development in the WT mice. However, 4-NQO exposure failed to induce tongue tumors or induction of FoxM1B expression in Grhl2 KO mice. Collectively, these results indicate that HPV-16 induces FoxM1B in part through GRHL2 transcriptional activity and that elevated FoxM1B level is required for oropharyngeal cancer development.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180214
[Lr] Last revision date:180214
[St] Status:Publisher
[do] DOI:10.1177/0022034518756071

  4 / 3087 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29432652
[Au] Autor:McGowan K; Ivanovski S; Acton C
[Ad] Address:School of Dentistry, Oral Health, Gold Coast Campus, Griffith University, Queensland, 4222, Australia.
[Ti] Title:Osteonecrosis of the jaws: a 14-year retrospective survey of hospital admissions.
[So] Source:Aust Dent J;, 2018 Feb 12.
[Is] ISSN:1834-7819
[Cp] Country of publication:Australia
[La] Language:eng
[Ab] Abstract:BACKGROUND: Osteonecrosis of the jaw (ONJ) is a serious complication of both radiation and antiresorptive therapies. This study aimed to determine how many patients have been treated for medication-related osteonecrosis of the jaws (MRONJ) and osteoradionecrosis (ORN), and whether the number of diagnoses has decreased over time with improved awareness and preventative measures. METHODS: Medical records at the Royal Brisbane & Women's Hospital, Gold Coast University Hospital, and Robina Hospital were reviewed to identify patients diagnosed with MRONJ and ORN between January 2003 - May 2017. Data on patient demographics, year of admission, and primary disease were analysed. RESULTS: 238 patients were diagnosed with ONJ, of which 74.4% were ORN and 25.6% were MRONJ. Tongue (24.6%), floor of mouth (17.3%), and tonsillar (15.1%) squamous cell carcinomas were the most common primary diseases associated with ORN, with a strong male predominance (80%). 52.5% of patients diagnosed with MRONJ were taking low-dose antiresorptives for osteoporosis (44.2%), rheumatoid arthritis (4.6%) or Paget's disease (3.3%), while 47.5% were oncology patients receiving high-dose antiresorptives. CONCLUSIONS: The number of patients diagnosed with MRONJ and ORN has trended upwards since 2003. ORN affected three times more patients than MRONJ, and patients on low-dose antiresorptives accounted for over half of the MRONJ cases. This article is protected by copyright. All rights reserved.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180212
[Lr] Last revision date:180212
[St] Status:Publisher
[do] DOI:10.1111/adj.12603

  5 / 3087 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27776338
[Au] Autor:Hong AM; Vilain RE; Romanes S; Yang J; Smith E; Jones D; Scolyer RA; Lee CS; Zhang M; Rose B
[Ad] Address:Sydney Medical School, The University of Sydney, NSW, Australia.
[Ti] Title:PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials.
[So] Source:Oncotarget;7(47):77010-77020, 2016 Nov 22.
[Is] ISSN:1949-2553
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:In this study, we examined PD-L1 expression by immunohistochemistry in 99 patients with tonsillar cancer and known human papillomavirus (HPV) status to assess its clinical significance. We showed that the pattern of PD-L1 expression is strongly related to HPV status. The PD-L1 positivity rate was 83.3% in HPV-positive cases and 56.9% in HPV-negative cases (p < 0.05). Patients with HPV-positive/PD-L1-positive cancer had significantly better event free survival and overall survival compared with patients with HPV-negative/PD-L1-negative cancer. Relative to those patients with HPV-negative/PD-L1-negative disease who had the highest risk of death, patients with HPV-positive/PD-L1-positive cancers had a 2.85 fold lower risk of developing an event (HR 0.35, 95% CI: 0.16-0.79) and a 4.5 fold lower risk of death (HR =0.22, 95% CI: 0.09-0.53). Our findings will help to guide future clinical trial design in immunotherapy based on PD-L1 expression in tonsillar cancer.
[Mh] MeSH terms primary: B7-H1 Antigen/metabolism
Papillomavirus Infections/metabolism
Tonsillar Neoplasms/metabolism
Tonsillar Neoplasms/virology
[Mh] MeSH terms secundary: Adult
Aged
Aged, 80 and over
Female
Humans
Lymphocytes, Tumor-Infiltrating
Male
Middle Aged
Papillomavirus Infections/pathology
Prognosis
Smoking/metabolism
Survival Analysis
Tonsillar Neoplasms/pathology
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (B7-H1 Antigen); 0 (CD274 protein, human)
[Em] Entry month:1802
[Cu] Class update date: 180212
[Lr] Last revision date:180212
[Js] Journal subset:IM
[Da] Date of entry for processing:161025
[St] Status:MEDLINE
[do] DOI:10.18632/oncotarget.12776

  6 / 3087 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29429426
[Au] Autor:Harris AS; Thomas RG; Passant CD
[Ad] Address:Aneurin Bevan University Health Board,Newport,Cardiff,Wales,UK.
[Ti] Title:Do patients with p16-positive oropharyngeal squamous cell carcinoma get more bone metastasis than p16-negative patients?
[So] Source:J Laryngol Otol;:1-5, 2018 Feb 12.
[Is] ISSN:1748-5460
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Oropharyngeal squamous cell carcinoma is thought to rarely metastasise to bone. This study hypothesised that in p16-positive disease there is a significant incidence of bony metastasis. METHODS: This was an ambispective cohort review. All patients with oropharyngeal squamous cell carcinoma diagnosed and treated at one centre were included. RESULTS: A total of 180 consecutive patients were identified over 5 years. Fifteen patients were excluded because of lack of p16 status, none of whom had bony metastasis. The final analysis included 165 patients: 48 (29.09 per cent) in the p16-negative group and 117 (70.91 per cent) in the p16-positive group. Ten patients (8.55 per cent) in the p16-positive group developed bony metastasis, compared with zero in the p16-negative group; this difference was statistically significant (p = 0.036). CONCLUSION: Expression of p16 was associated with an increased incidence in bony metastasis in this cohort. This is the first study to explore this specific question.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180212
[Lr] Last revision date:180212
[St] Status:Publisher
[do] DOI:10.1017/S0022215118000051

  7 / 3087 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29277098
[Au] Autor:Pham TA; Berkowitz RG
[Ad] Address:1 Department of Otolaryngology, Royal Children's Hospital, Melbourne, VIC, Australia.
[Ti] Title:Targeted Tonsillar Biopsy for Unilateral Tonsillar Enlargement.
[So] Source:Ann Otol Rhinol Laryngol;127(2):113-117, 2018 Feb.
[Is] ISSN:1943-572X
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Unilateral tonsillar enlargement (UTE) is not an uncommon incidental finding. Lymphoma is the most common malignancy of the tonsils in children and presents with tonsillar enlargement. METHODS: This is a retrospective case series of all cases of histopathological analysis of tonsillectomy specimens at a single pediatric tertiary hospital between 1996 and 2015. Patients either had a preoperative indication (n = 53) for pathological testing or indications based on intraoperative findings (n = 88). Of the preoperative group, 17 patients had tonsillectomy for UTE alone. In 72% of cases, the side of perceived unilateral enlargement was confirmed at histopathological assessment. RESULTS: Zero cases of suspected malignancy were identified on testing. CONCLUSION: There is a very low prevalence of unsuspected and suspected malignancy in routine and targeted examination of tonsillar specimens. It is reasonable to test based on other clinical findings and risk factors such as immunosuppression.
[Mh] MeSH terms primary: Biopsy/methods
Palatine Tonsil/pathology
[Mh] MeSH terms secundary: Adolescent
Child
Child, Preschool
Diagnosis, Differential
Female
Humans
Hypertrophy/pathology
Hypertrophy/surgery
Incidental Findings
Infant
Lymphoma/pathology
Male
Retrospective Studies
Tonsillar Neoplasms/pathology
Tonsillectomy
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180123
[Lr] Last revision date:180123
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:171227
[St] Status:MEDLINE
[do] DOI:10.1177/0003489417749252

  8 / 3087 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29245278
[Au] Autor:Wu Y; Zhu Z; Chen Y; Chai Y
[Ad] Address:Department of Thoracic Surgery, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
[Ti] Title:Tonsillar metastasis of nonsmall cell lung cancer with G719S mutation in exon 18: A case report.
[So] Source:Medicine (Baltimore);96(49):e9003, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:RATIONALE: Lung cancer has the highest mortality of all malignant tumors and is becoming the leading cause of death in China. Surgical resection is the best treatment for early non-small-cell lung carcinoma. But postoperative tumor recurrence is very common. Brain, bone and liver are the most common metastatic sites of lung cancer. PATIENT CONCERNS: A 59-year-old woman was admitted to our hospital finding a lung nodule in physical examination. No other obvious symptoms were obsessed in this patient. No remarkable abnormality was detected in preoperative laboratory tests and physical examination. DIAGNOSES: A ground-glass nodule was detected on the left inferior lobe in the imaging examination. No metastases were detected before the surgery and early-stage lung cancer was supposed. INTERVENTION: This patient underwent a radical resection of lung cancer successfully and enjoyed a peaceful postoperative rehabilitation. OUTCOMES: Although pathological diagnosed confirmed early stage lung adenocarcinoma (T1N0M0). The patient had tumor recurrence 7 months after operation. Gene sequencing confirmed the G719S mutation in exon 18 of the EGFR gene and target therapy, chemotherapy and radiotherapy were all given to this patient successively, but they were all unresponsive. The patient died 26 months after surgery. LESSONS: We herein first report G719S mutation in lung adenocarcinoma with tonsillar metastasis. Generally, the tumor responded poorly to treatment and progressed quickly, which didn't achieve the desired effect. G719S mutant is supposed to be the cause of poor responsive to treatment.
[Mh] MeSH terms primary: Carcinoma, Non-Small-Cell Lung/pathology
Genes, erbB-1/genetics
Lung Neoplasms/pathology
Tonsillar Neoplasms/secondary
[Mh] MeSH terms secundary: Carcinoma, Non-Small-Cell Lung/genetics
Carcinoma, Non-Small-Cell Lung/therapy
China
Female
Humans
Lung Neoplasms/genetics
Lung Neoplasms/therapy
Middle Aged
Tonsillar Neoplasms/genetics
Tonsillar Neoplasms/therapy
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180105
[Lr] Last revision date:180105
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:171217
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009003

  9 / 3087 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29100961
[Au] Autor:Hoffmann M; Quabius ES; Tribius S; Gebhardt S; Görögh T; Hedderich J; Huber K; Dunst J; Ambrosch P
[Ad] Address:Department of Otorhinolaryngology, Head and Neck Surgery, Christian-Albrechts-University Kiel, D-24105 Kiel, Germany. Electronic address: markus.hoffmann@uksh.de.
[Ti] Title:Influence of HPV-status on survival of patients with tonsillar carcinomas (TSCC) treated by CO -laser surgery plus risk adapted therapy - A 10 year retrospective single centre study.
[So] Source:Cancer Lett;413:59-68, 2018 Jan 28.
[Is] ISSN:1872-7980
[Cp] Country of publication:Ireland
[La] Language:eng
[Ab] Abstract:The positive prognostic value of HPV-infections in oropharyngeal squamous cell cancer (OSCC) patients has led to the initiation of prospective clinical trials testing the value of treatment de-escalation. It is unclear how to define patients potentially benefiting from de-escalated treatment, whether a positive smoking history impacts survival data and what kind of de-escalation might be best. Here, we investigate the effect of HPV-status, smoking habit and treatment design on overall survival (OS) and progression free survival (PFS) of 126 patients with tonsillar SCC (TSCC) who underwent CO -laser-surgery and risk adapted adjuvant treatment. HPV-DNA-, HPV-mRNA-, and p16 -expression were analysed and results were correlated to OS and PFS. Factors tested for prognostic value included HPV-status, p16 -protein expression, therapy and smoking habit. Log rank test and p-values ≤0.05 defined significant differences between groups. The highest accuracy of data with highest significance in this study is given when the HPV-RNA-status is considered. Using p16 -expression alone or in combination with HPV-DNA-status, would have misclassified 23 and 7 patients, respectively. Smoking fully abrogates the positive impact of HPV-infection in TSCC on survival. Non-smoking HPV-positive TSCC patients show 10-year OS of 100% and 90.9% PFS when treated with adjuvant RCT. The presented data show that high-precision HPV-detection methods are needed, specifically when treatment decisions are based on the results. Furthermore, smoking habit should be included in all studies and clinical trials testing HPV-associated survival. Adjuvant RCT especially for HPV-positive non-smokers may help to avoid distant failure.
[Mh] MeSH terms primary: Carcinoma, Squamous Cell/surgery
Head and Neck Neoplasms/surgery
Laser Therapy/instrumentation
Lasers, Gas/therapeutic use
Papillomaviridae/isolation & purification
Papillomavirus Infections/virology
Tonsillar Neoplasms/surgery
[Mh] MeSH terms secundary: Adult
Aged
Aged, 80 and over
Biomarkers, Tumor/analysis
Carcinoma, Squamous Cell/chemistry
Carcinoma, Squamous Cell/mortality
Carcinoma, Squamous Cell/virology
Chemoradiotherapy, Adjuvant
Cyclin-Dependent Kinase Inhibitor p16/analysis
DNA, Viral/genetics
Disease Progression
Disease-Free Survival
Female
Head and Neck Neoplasms/chemistry
Head and Neck Neoplasms/mortality
Head and Neck Neoplasms/virology
Human Papillomavirus DNA Tests
Humans
Immunohistochemistry
Kaplan-Meier Estimate
Laser Therapy/adverse effects
Laser Therapy/mortality
Lasers, Gas/adverse effects
Male
Middle Aged
Neck Dissection
Papillomaviridae/genetics
Papillomavirus Infections/diagnosis
Predictive Value of Tests
Proportional Hazards Models
RNA, Messenger/genetics
RNA, Viral/genetics
Radiotherapy, Adjuvant
Retrospective Studies
Risk Factors
Smoking/adverse effects
Smoking/mortality
Time Factors
Tonsillar Neoplasms/chemistry
Tonsillar Neoplasms/mortality
Tonsillar Neoplasms/virology
Treatment Outcome
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Biomarkers, Tumor); 0 (Cyclin-Dependent Kinase Inhibitor p16); 0 (DNA, Viral); 0 (P16 protein, human); 0 (RNA, Messenger); 0 (RNA, Viral)
[Em] Entry month:1712
[Cu] Class update date: 171204
[Lr] Last revision date:171204
[Js] Journal subset:IM
[Da] Date of entry for processing:171105
[St] Status:MEDLINE

  10 / 3087 MEDLINE  
              first record previous record
select
to print
Photocopy

[PMID]: 28982840
[Au] Autor:Näsman A; Bersani C; Lindquist D; Du J; Ramqvist T; Dalianis T
[Ad] Address:Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
[Ti] Title:Human Papillomavirus and Potentially Relevant Biomarkers in Tonsillar and Base of Tongue Squamous Cell Carcinoma.
[So] Source:Anticancer Res;37(10):5319-5328, 2017 10.
[Is] ISSN:1791-7530
[Cp] Country of publication:Greece
[La] Language:eng
[Ab] Abstract:Human papillomavirus (HPV)-positive tonsillar- and base of tongue cancer is increasing epidemically and has much better outcome than corresponding HPV-negative cancer and most other head and neck cancers with around 80% 3-year disease free survival with conventional radiotherapy and surgery. Consequently, most HPV-positive cancer patients may not require the intensified chemoradiotherapy given to many head and neck cancer patients and would, with tapered treatment, avoid several severe side-effects. Moreover, intensified therapy has not improved survival and treatment alternatives are needed. To identify patients eligible for tapered or targeted therapy, additional biomarkers are required. Several studies have, therefore, focused on finding predictive markers, some of which are also potentially targetable. To conclude, better-tailored therapy, either as tapered or targeted, is important for increasing numbers of patients with HPV-positive tonsillar- and base of tongue cancer. This review deals with some of these issues and presents some promising markers.
[Mh] MeSH terms primary: Biomarkers, Tumor/metabolism
Carcinoma, Squamous Cell/metabolism
Head and Neck Neoplasms/metabolism
Papillomaviridae/isolation & purification
Papillomavirus Infections/complications
Tongue Neoplasms/metabolism
Tonsillar Neoplasms/metabolism
[Mh] MeSH terms secundary: Biomarkers, Tumor/genetics
Carcinoma, Squamous Cell/genetics
Carcinoma, Squamous Cell/therapy
Carcinoma, Squamous Cell/virology
Head and Neck Neoplasms/genetics
Head and Neck Neoplasms/therapy
Head and Neck Neoplasms/virology
Human Papillomavirus DNA Tests
Humans
Neoplasm Staging
Neoplastic Stem Cells/metabolism
Neoplastic Stem Cells/virology
Papillomaviridae/classification
Papillomaviridae/genetics
Papillomavirus Infections/therapy
Papillomavirus Infections/virology
Patient Selection
Predictive Value of Tests
Tongue Neoplasms/genetics
Tongue Neoplasms/therapy
Tongue Neoplasms/virology
Tonsillar Neoplasms/genetics
Tonsillar Neoplasms/therapy
Tonsillar Neoplasms/virology
Treatment Outcome
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (Biomarkers, Tumor)
[Em] Entry month:1710
[Cu] Class update date: 171016
[Lr] Last revision date:171016
[Js] Journal subset:IM
[Da] Date of entry for processing:171007
[St] Status:MEDLINE


page 1 of 309 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information